FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							( )				j je.										
Name and Address of Reporting Person*						2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC [ alxn ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
BOWDISH KATHERINE S																Direc	rector		10% O	wner	
(Last)	(Eir	ret) (	Middlo		dixi	u j									X	Office belov	er (give title v)		Other ( below)	specify	
	(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year)									Sr. Vice President						
C/O ALEXION PHARMACEUTICALS INC					04/	04/16/2004															
352 KNOTTER DRIVE													_								
					4. If	Ame	endment	, Date o	f Origina	l Filed	I (Month/Da	ay/Ye	ear)		Indivi ne)	dual o	r Joint/Group	Filing	(Check A	pplicable	
(Street)														٦	X	Form	n filed by One	e Reno	rtina Pers	on	
CHESHI	RE CT	Γ (	06410														n filed by Mor		•		
																Pers		C triair	One Rep	or urig	
(City)	(St	ate) (	Zip)																		
		Tabl	e I - Nor	า-Deriv	ative	Se	curitie	s Acc	quired,	Dis	posed o	f, o	r Ben	efici	ally (	Owne	ed				
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)				Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed Code (Instr. 5)		ities Acquired (A) d Of (D) (Instr. 3, 4			4 and Seci Ben		cially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount		(A) or (D)	Price		Transa	action(s) 3 and 4)			(111511.4)	
Common Stock, par value \$.0001 04/16/				/2004				S		4,300	00 D \$		\$23	.27	37,196			D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	Date, Transaction					6. Date Exercisab Expiration Date (Month/Day/Year)		Ame Sec Und Der Sec		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)				9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ov Fo Di or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Titl	or Nu of	nount mber ares							

**Explanation of Responses:** 

Katherine S. Bowdish

04/20/2004

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $<sup>^{\</sup>star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).